Clinical Safety Profile of Bruton’s Tyrosine Kinase (BTK) Inhibitors in Chronic Lymphocytic Leukaemia: A Real-World Ambispective Study From India
Cureus · 19.05.2026
DOI: 10.7759/cureus.109238 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cureus, erschienen am 19.05.2026. Verfasst von Arya Pradhan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The Gujarat Cancer and Research Institute, Ahmedabad, IND. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, The Gujarat Cancer and Research Institute, Ahmedabad, IND.
Zitieren
APA
Pradhan, A., & Panchal, H. P. (2026). Clinical Safety Profile of Bruton’s Tyrosine Kinase (BTK) Inhibitors in Chronic Lymphocytic Leukaemia: A Real-World Ambispective Study From India. Cureus. https://doi.org/10.7759/cureus.109238
Vancouver
Pradhan A, Panchal HP. Clinical Safety Profile of Bruton’s Tyrosine Kinase (BTK) Inhibitors in Chronic Lymphocytic Leukaemia: A Real-World Ambispective Study From India. Cureus. 2026. doi:10.7759/cureus.109238
BibTeX
@article{Pradhan2026,
author = {Pradhan, Arya and Panchal, Harsha P},
title = {Clinical Safety Profile of Bruton’s Tyrosine Kinase (BTK) Inhibitors in Chronic Lymphocytic Leukaemia: A Real-World Ambispective Study From India},
journal = {Cureus},
year = {2026},
doi = {10.7759/cureus.109238}
}
EUVIMED